Keywords
ankylosing spondylitis; tumor necrosis factor-α inhibitors; efficiency; safety
Abstract
A review of recommendations for the use of tumor necrosis factor α (TNF-α) inhibitors in patients with ankylosing spondylitis (AS) is presented. The data on the efficacy of TNF-α in patients with AS are presented. On the basis of international and domestic recommendations, ndications for the appointment of this therapy, criteria for assessing its effectiveness and safety are formulated.